Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection

Digestive and Liver Disease

Volumn 47, Issue 9, 2015, Pages 811-814

  Wehmeyer, Malte H ^a   Jordan, Sabine ^a   Lüth, Stefan ^a   Hartl, Johannes ^a   Stoehr, Albrecht ^b   Eißing, Christiane ^a   Lohse, Ansgar W ^a,c   Petersen, Jörg ^b   Buggisch, Peter ^b   Schulze zur Wiesch, Julian ^a,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c German Center for Infection Research (DZIF)   (Germany)

Author keywords

Direct acting antivirals; HCV; Sustained virological response; SVR

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SOFOSBUVIR; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LEUKOPENIA; MALE; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN DISEASE; THROMBOCYTOPENIA; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; GENETICS; GERMANY; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TERTIARY CARE CENTER; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GERMANY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TERTIARY CARE CENTERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84939256041     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.05.018     Document Type: Article

References (11)

1. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine 2013, 368:1878-1887.
2. Jacobsen I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine 2013, 368:1867-1877.
3. Ruane P.J., Ain D., Stryker R., et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. Journal of Hepatology 2015, 62:1040-1046.
4. Wantuck J.M., Ahmed A., Nguyen M.H. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Alimentary Pharmacology and Therapeutics 2014, 39:137-147.
5. Wehmeyer M.H., Eißing F., Jordan S., et al. Safety and efficacy of protease inhibitor based combination therapy in a single-center real-life cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterology 2014, 14:87.
6. Hezode C., Hirschfield G.M., Ghesquiere W., et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015, 64:948-956.
7. Moreno C., Hezode C., Marcellin P., et al. Efficacy and safety of simeprevir with pegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. Journal of Hepatology 2015, 62:1047-1055.
8. Hezode C., Asselah T., Reddy K.R., et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015, 10.1016/S0140-6736(15)60159-3.
9. Kapoor R., Kohli A., Sidharthan A., et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology 2014, 60(321A). [abstract].
10. Hassanein T., Sims K.D., Bennett M., et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. Journal of Hepatology 2015, 62:1204-1206.
11. Ragheb M.M., Nemr N.A., Kishk R.M., et al. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver International 2014, 34:890-895.